Should Precision Oxygen Therapeutics distinguish oxygen exposure, transport, delivery and tissue response?
This scientific question asks whether oxygen-directed therapeutics should be evaluated across distinct physiological layers rather than through hemoglobin concentration, oxygen exposure or any single downstream endpoint alone. The proposed framework separates oxygen exposure, transport, delivery and tissue response, while keeping direct evidence, contextual interpretation and author hypothesis explicitly distinct.
Concentration should not be confused with function.
Rogers and colleagues introduced lung-to-tissue oxygen flux, L-TOF, as an in vitro metric for comparing oxygen-delivery potency across fresh and stored red-cell products and formulations containing hemoglobin-based oxygen carriers.
The authors explicitly note that transfusion dosing is commonly based on hemoglobin levels without accounting for differences in oxygen-delivery potential between products.
The relevant development question is functional.
For BHOC development, the central question is not simply how many grams of hemoglobin are administered. The more useful development question is how much reproducible oxygen-delivery function a defined dose provides under relevant physiological conditions.
A functional framework could eventually connect formulation attributes, oxygen affinity, cooperativity, Bohr-effect responsiveness, oxygen unloading, microcirculation and downstream physiological endpoints. Those relationships have to be demonstrated, not assumed.
Equal volume or equal hemoglobin does not automatically mean equal modeled oxygen-delivery potency.
Chu and colleagues (2026) provide a complementary analytical framework for oxygen-supply efficiency. Their approach integrates oxygen affinity (P50), cooperativity through the Hill coefficient, Bohr-effect responsiveness through an acid-base sensitivity index, and theoretical oxygen-release capacity under simulated lung and tissue conditions. The study included red blood cells, bovine hemoglobin and a dextran-modified bovine hemoglobin conjugate.
Controlled hyperoxia produced biological signals without amplifying the prespecified inflammatory endpoint.
Linden and colleagues reported the HIPI randomized, double-blind, placebo-controlled human study in Thorax in 2026. Twenty-two healthy adult volunteers underwent inhaled lipopolysaccharide challenge and were randomized 1:1 to receive either hyperoxia by high-flow nasal oxygen at FiO₂ 1.0 and 60 L/min for 6 hours, or synthetic medical air.
The prespecified primary endpoint, bronchoalveolar lavage IL-8 at 6 hours, did not differ significantly between groups: 375.7 pg/mL in the hyperoxia group versus 331.9 pg/mL in the medical-air group (p=0.33). The investigators also reported no between-group differences in BAL cytokines or markers of systemic inflammation.
At the same time, hyperoxia was associated with an approximately fourfold increase in BAL reduced glutathione, reported with an unadjusted p value of 0.02, and with a distinct whole-blood transcriptional response at 24 hours involving 175 differentially expressed genes after multiple-testing adjustment (padj<0.05). The reported gene sets included pathways related to extracellular matrix remodelling, platelet activation and endothelial repair.
Absence of a change in one endpoint is not the same as absence of biological response.
The HIPI study is useful because different biological layers gave different signals. The prespecified inflammatory endpoint was not significantly amplified, while redox and transcriptomic changes were detected. This supports careful separation of the biological compartment, endpoint and time point being measured.
The study did not compare different oxygen doses or exposure durations. It therefore does not by itself establish a dose-response or duration-response relationship. It also does not establish that the glutathione change was beneficial or harmful. The increase is most appropriately treated as evidence of altered pulmonary redox biology under the conditions studied.
Likewise, transcriptomic associations with platelet activation, extracellular matrix remodelling or endothelial repair are molecular pathway signals. They should not be presented as proof of corresponding clinical effects.
Oxygen exposure, oxygen transport, tissue delivery and biological response are related, but they are not interchangeable.
Within this framework, the Rogers and Chu studies address analytical properties of oxygen transport and release. HIPI addresses a different part of the system: human biological responses following a defined oxygen exposure.
The distinction is important for Precision Oxygen Therapeutics. Increasing inspired oxygen concentration changes the oxygen-exposure side of physiology. A hemoglobin oxygen carrier is intended to modify oxygen-carrying and delivery function. These interventions should not be assumed to produce the same biological effects simply because both involve oxygen.
From oxygen concentration to controlled oxygen-delivery function.
A broader research hypothesis is that future oxygen-directed therapeutics may need to be characterized not only by how much oxygen is present in blood, but also by where, when and under what physiological conditions oxygen is carried, released and delivered, and by how tissues respond.
HIPI does not prove this hypothesis, and it does not provide evidence of BHOC efficacy or safety. Its relevance is mechanistic and contextual: it shows in humans that a defined oxygen exposure can generate measurable biological responses that are not captured by a single prespecified inflammatory endpoint.